Search

everythinglearnresearchcommunity

for

Search:↓

CDK4/6 inhibitors generally maintain quality of life in metastatic breast cancer patients, except for some side effects like diarrhea and hair loss.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Abatacept may help some people with alopecia areata regrow hair.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

A patient's grey hair regained color during treatment with adalimumab.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Transgender men need personalized cancer care and continued testosterone therapy for well-being.

CTP-543 is generally safe for treating alopecia areata.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Tofacitinib might be used to treat hair loss.

A woman's hair turned white after taking a cancer drug called dasatinib.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Cetuximab can cause eyelash growth, which is rare but manageable.

Axitinib treatment turned a man's grey hair back to black.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Rituximab improved her dermatomyositis better than usual treatments.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Radiotherapy affects mitochondrial-related genes in metastatic breast cancer cells.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.